The approach bub undertook over the past year is a bit doggy. Yes they did great on the US expansion. Im mainly refer to the share incentive plan with Wills Chinese trading partner. Yes they may have made $2mil EBITDA, but its is very likely we ended up more than $5mil of share to Wills for free at a cost of shareholder. I dont consider that as making a profit for the last FY. And the fact that CEO is doubling there incomes before shareholder getting anything, or even the formal last FY earnibg figure released.
We all expected FDA will work on the long term supply arrangement and until all the details are confirm and released, nothing has been warrented.
apart from that, yes they did great with US expansion and the future is bright, and risky too.
Ann: FDA Framework and New Operation Fly Formula, page-11
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BUB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
-0.005(3.85%) |
Mkt cap ! $111.6M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.0¢ | 12.0¢ | $173.7K | 1.393M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 1095464 | 24 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| BUB (ASX) Chart |